Skip to content

Released Nov 5, 2025, before the open

10-Q filed Nov 5, 2025, 36 days after period end · 0001628280-25-049238

Q3 2025 · 10-Q
Revenue$8.15M+4.4% vs Q3 2024+7.9% vs Q2 2025
Net Income-$15.85MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.25N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$18,501,000N/M
Operating Cash Flowderived-$18,860,000N/M
Free Cash Flowderived-$18,860,000N/M
Margins · derived
Operating margin-226.9%+78.6 pt vs Q3 2024
Net margin-194.4%+50.5 pt vs Q3 2024

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Revenue$8.15M$7.81M$17.48M$6.63M
Net Income-$15.85M-$19.12M-$14.35M-$25.77M
EPS Diluted-$0.25-$0.31-$0.34-$0.62

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR